CA-ARGONAUT-MANUF-SVCS
5.3.2024 13:01:36 CET | Business Wire | Press release
Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45 million financing to support its new drug product fill / finish expansion. This expansion in Carlsbad, CA, underway since early 2023, includes a new dedicated facility with a state-of-the-art isolator-based filling line that more than quadruples Argonaut’s existing drug product fill / finish capacity and augments existing vial filling capabilities with the ability to pre-fill syringes and cartridges for clinical and commercial supply. Argonaut expects to have fully validated the facility and all equipment in 2025.
The financing was led by NewVale Capital, a growth equity fund focused on innovative pharmaceutical and life science services businesses, with participation from existing majority investor Telegraph Hill Partners, and other current investors.
Wayne Woodard, founder and CEO of Argonaut, commented: “Argonaut is uniquely positioned to address the manufacturing challenges that biopharma innovators face related to sterile fill / finish of complex and high-value drug products. We remain laser focused on leveraging our experienced team’s commitment to flexibility and client satisfaction while prioritizing quality and compliance. The recent commitment from NewVale Capital and the continued support of Telegraph Hill Partners paves a straight path to capacity expansion and fulfillment of our mission to become the world’s best Drug Product Manufacturing solutions provider for our clients.”
“We are thrilled to partner with Telegraph Hill to support the experienced team at Argonaut, building upon their strong foundation,” said Todd Holmes, Managing Partner of NewVale Capital. “For years, small- and medium-sized biopharma companies have struggled to find reliable, high-quality fill / finish capabilities from providers that prioritize their molecules. With this capital infusion, we can further enable Argonaut’s mission that no innovator, regardless of size, should be waitlisted behind larger pharma or be forced to compromise on quality when trying to bring critical therapies to patients.”
Argonaut’s FDA-registered facilities are compliant with 21 CFR parts 210, 211, and 820 and offer highly flexible and scalable solutions for a broad range of biopharmaceuticals including monoclonal antibodies, proteins, peptides, oligonucleotides, and small molecules. Additionally, Argonaut maintains an ISO 13485:2016 certification to produce drug-device combination products. Argonaut’s quality systems have been successfully audited by many biopharma customers and global regulatory agencies including the FDA and PMDA.
“The recent consolidation in the aseptic fill / finish market has highlighted the need for additional capacity to ensure patients have uninterrupted access to critical life-saving and life-extending therapies,” stated Chris Duffy, SVP/GM of Biopharma Services at Argonaut. “Our deep expertise in fill / finish, coupled with our planned expansion will help address this need for our clients and we remain ready to take on new projects.”
RBC Capital Markets LLC served as exclusive placement agent to Argonaut.
About Argonaut Manufacturing Services
Argonaut Manufacturing Services is an FDA-registered cGMP contract development and manufacturing organization (CDMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill / finish capabilities feature state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecules, and vaccines. Diagnostic manufacturing capabilities include proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the biopharma, life science, and molecular diagnostics industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. For more information, visit: www.argonautms.com.
About Telegraph Hill Partners
Founded in 2001, Telegraph Hill Partners invests in life science, medical device, and healthcare technology companies. For more information, visit: www.telegraphhillpartners.com.
About NewVale Capital
Founded in 2022, NewVale Capital is a growth equity firm that focuses on supporting the next generation of life science services companies. The firm invests in proven, revenue-generating services businesses across the life science ecosystem that are helping to bring medicines to patients. For more information, visit: www.newvalecapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305644445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 13:00:00 CEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
Infobip Launches PitchMate — An AI Fan Companion for Global Football2.7.2026 12:00:00 CEST | Press release
Two AI agents. Two global sports. One platform redefining what it means to be a fan. Global AI-first cloud communications platform Infobip launched PitchMate, a new AI-powered conversational agent that brings football fans closer to the action of the world’s biggest football tournament. Purpose-built for the global football audience, PitchMate joins the TGR Haas F1 Team RaceMate — Infobip’s AI fan engagement solution for the TGR Haas F1 Team — in demonstrating how conversational AI is transforming fan engagement across sports worldwide. RaceMate, launched last April for this year’s motorsport season, is an AI agent on WhatsApp and Apple Messages for Business that puts TGR Haas F1 Team fans at the center of the action. It delivers real-time race data, personalized content, team radio highlights, trivia, and native multilingual support, turning passive viewers into active participants through natural, human-like conversations across every race weekend. Since its launch, RaceMate has reac
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies2.7.2026 11:00:00 CEST | Press release
Acquisition brings together Besins Healthcare's hormonal health leadership and UniD's expertise in the development and manufacturing of advanced polymer based pharmaceutical formulations.1UniD Manufacturing to become Besins Healthcare PharmTech, serving as a strategic innovation hub within the company while continuing to serve its clients. Besins Healthcare, a global pharmaceutical company specializing in hormonal health, today announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognized expertise in long-acting drug delivery technologies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701779777/en/ Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies This acquisition brings together two highly compatible areas. Besins Healthcare bri
ROYC Selected by Slättö as Structuring and Platform Solution for Luxembourg Feeder Fund2.7.2026 10:45:00 CEST | Press release
ROYC, a leading global structuring and platform provider, today announced that Slättö, a Nordic private markets real estate firm, has selected ROYC to establish and manage a Luxembourg-domiciled feeder fund designed to efficiently aggregate individual subscriptions from professional investors. The Luxembourg-domiciled vehicle will be fully structured and administered on ROYC’s proprietary platform, delivering investors a seamless digital experience with real-time portfolio access, automated reporting, and efficient global distribution. ROYC streamlines onboarding and governance, standardizes legal documentation, and broadens access to capital. “Private markets are undergoing a structural shift as global banks and wealth platforms increasingly seek efficient access to high-quality private equity strategies. By combining our deep structuring expertise with ROYC’s digital operating infrastructure, we enable leading managers like Slättö to launch investor-ready vehicles rapidly while deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom